search
Back to results

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (GetGoal-O)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Lixisenatide (AVE0010)
Placebo
Antidiabetic background therapy
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

  • Older participants, aged 70 years and above, with T2DM inadequately controlled on their current anti-diabetic pharmaceutical treatment regimen.
  • Signed written informed consent.

Exclusion criteria:

  • At screening HbA1c ≤7.0% or >10% (Acknowledging that the threshold of 7% may not be appropriate for all older participants and that this was the responsibility of the investigator to include the participant based on an individual evaluation of the expected benefits of better glycemic control versus risk of hypoglycemia).
  • At screening participants on both basal insulin and sulfonylurea or basal insulin and meglitinides.
  • At screening FPG >250 mg/dL (>13.9 mmol/L).
  • Type 1 diabetes mellitus or history of ketoacidosis within one year prior to the screening visit.
  • Type 2 diabetes mellitus diagnosed less than 1 year prior to screening.
  • Anti-diabetic treatment not at a stable regimen or initiated within the last 3 months prior to screening.
  • Treatment within the 3 months preceding the screening with other anti-diabetic agent than allowed background therapy. Allowed therapy includes metformin, sulfonylurea (except glibenclamide >10mg, gliclazide >160mg), meglitinides (except repaglinide >6mg), pioglitazone and basal insulin and should follow local product circulars and labeling restrictions for the study population.
  • Participants who had been on an approved or an investigational Glucagon-like peptide 1 (GLP-1) medication (exenatide, liraglutide, lixisenatide or others).
  • History of severe hypoglycemia associated with symptoms unawareness or results in unconsciousness/coma/seizure in the 6 months prior to screening.
  • BMI <22 or >40 kg/m^2.
  • Malnutrition assessed clinically by the investigator or any sub-investigator and by Mini-Nutritional Assessment-Short Form (MNA-SF) score <12 in countries (the judgment of the investigator prevails on questionnaires scores).
  • Cognitive disorder and dementia assessed clinically by the investigator or any sub investigator and by Mini Mental State Examination (MMSE) score <24 (the judgment of the investigator prevails on questionnaires scores), or any neurologic disorder that affected the participant's ability to participate in the study.
  • Participant who had a glomerular filtration rate (eGFR) (using the Modification of Diet in Renal Disease (MDRD) formula <30ml/min/1.73m^2).
  • Participant with severe or uncontrolled disease, or any clinically significant abnormality identified on physical examination or investigational clinical procedure that, in the judgment of the investigator or any sub-investigator, would preclude safe completion of the study or constrains efficacy assessment.
  • Laboratory findings at the time of screening:

    • Amylase and/or lipase: >3 times the upper limit of the normal (ULN) laboratory range
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times ULN
    • Calcitonin >20 pg/mL (5.9 pmol/L).
  • Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (i.e. worsening) and not controlled (i.e. prolonged nausea and vomiting) gastroesophageal reflux disease within 6 months prior to screening.
  • History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.
  • Personal or immediate family history of medullary thyroid cancer or genetic conditions that predisposed to medullary thyroid cancer (e.g., multiple endocrine neoplasia syndromes).

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 840010
  • Investigational Site Number 840015
  • Investigational Site Number 840003
  • Investigational Site Number 840012
  • Investigational Site Number 840002
  • Investigational Site Number 840008
  • Investigational Site Number 840004
  • Investigational Site Number 840017
  • Investigational Site Number 840009
  • Investigational Site Number 840016
  • Investigational Site Number 840006
  • Investigational Site Number 840014
  • Investigational Site Number 840011
  • Investigational Site Number 840007
  • Investigational Site Number 036002
  • Investigational Site Number 036006
  • Investigational Site Number 036004
  • Investigational Site Number 036005
  • Investigational Site Number 036001
  • Investigational Site Number 036003
  • Investigational Site Number 100002
  • Investigational Site Number 100005
  • Investigational Site Number 100003
  • Investigational Site Number 100004
  • Investigational Site Number 100001
  • Investigational Site Number 124003
  • Investigational Site Number 124007
  • Investigational Site Number 124002
  • Investigational Site Number 124001
  • Investigational Site Number 124005
  • Investigational Site Number 124006
  • Investigational Site Number 124008
  • Investigational Site Number 124004
  • Investigational Site Number 208005
  • Investigational Site Number 208001
  • Investigational Site Number 208004
  • Investigational Site Number 208002
  • Investigational Site Number 208003
  • Investigational Site Number 276005
  • Investigational Site Number 276004
  • Investigational Site Number 276002
  • Investigational Site Number 276001
  • Investigational Site Number 276006
  • Investigational Site Number 276007
  • Investigational Site Number 276008
  • Investigational Site Number 276003
  • Investigational Site Number 578001
  • Investigational Site Number 578005
  • Investigational Site Number 578003
  • Investigational Site Number 578006
  • Investigational Site Number 578004
  • Investigational Site Number 604001
  • Investigational Site Number 604011
  • Investigational Site Number 604005
  • Investigational Site Number 604003
  • Investigational Site Number 604006
  • Investigational Site Number 604002
  • Investigational Site Number 604007
  • Investigational Site Number 604008
  • Investigational Site Number 616004
  • Investigational Site Number 616003
  • Investigational Site Number 616001
  • Investigational Site Number 616002
  • Investigational Site Number 616006
  • Investigational Site Number 710003
  • Investigational Site Number 710002
  • Investigational Site Number 710004
  • Investigational Site Number 724001
  • Investigational Site Number 724005
  • Investigational Site Number 724006
  • Investigational Site Number 724003
  • Investigational Site Number 724002
  • Investigational Site Number 724004
  • Investigational Site Number 752006
  • Investigational Site Number 752007
  • Investigational Site Number 752002
  • Investigational Site Number 752004
  • Investigational Site Number 752003
  • Investigational Site Number 752001
  • Investigational Site Number 826003
  • Investigational Site Number 826001
  • Investigational Site Number 826002
  • Investigational Site Number 826004

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Lixisenatide

Placebo

Arm Description

Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.

Placebo (matched to lixisenatide) QD for 24 Weeks.

Outcomes

Primary Outcome Measures

Absolute Change in HbA1c From Baseline to Week 24
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last on-treatment observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed=participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.

Secondary Outcome Measures

Change in 2-Hour PPG From Baseline to Week 24
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Change in Average 7-point SMPG Profiles From Baseline to Week 24
Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime three times in a week before baseline, before visit Week 12 and before visit week 26 and the average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug.
Change in Body Weight From Baseline to Week 24
Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug.
Change in FPG From Baseline to Week 24
Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug.
Percentage of Participants Requiring Rescue Therapy During 24 Week Treatment Period
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG >270 mg/dL (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >9%.
Change in Plasma Glucose Excursions From Baseline to Week 24
Plasma glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the liquid standardized breakfast meal test, before study drug administration. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Change in Total Daily Basal Insulin Dose From Baseline to Week 24 (in Participants Who Took Basal Insulin as Background Therapy)
Change in basal insulin dose was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Percentage of Participants With Symptomatic and Severe Symptomatic Hypoglycemia
Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the participant required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.
Percentage of Participants With HbA1c Reduction >0.5% at Week 24 and Did Not Experienced Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia
The on-treatment period for HbA1c assessment was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. The on-treatment period for symptomatic hypoglycemia assessment was defined as the time from the first dose of study drug up to 1 day after the last dose of study drug.
Percentage of Participants With Gastrointestinal Disorders

Full Information

First Posted
February 22, 2013
Last Updated
March 21, 2017
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT01798706
Brief Title
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Acronym
GetGoal-O
Official Title
A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
June 2013 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Primary objective: - To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who are inadequately controlled with their current anti-diabetic treatment regimen. Main secondary objective: - To assess the safety and tolerability of lixisenatide compared to placebo in older T2DM participants (including occurrence of documented (Plasma Glucose PG < 60 mg/dL) symptomatic hypoglycemia and gastrointestinal side effects). Other secondary objectives: To assess the effect of lixisenatide compared to placebo after 24-week treatment on: Fasting plasma glucose (FPG); During liquid standardized breakfast meal challenge test : 2 hour- Postprandial Plasma Glucose (PPG) and Plasma Glucose Excursion; 7-point Self-monitored plasma glucose (SMPG) profile; Body weight; Change in total daily dose of basal insulin (if taken); Percentage of participants requiring rescue therapy Safety and tolerability; To assess lixisenatide pharmacokinetic profile; To assess anti-lixisenatide antibody development.
Detailed Description
Approximately 31 weeks including 24 week treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
350 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lixisenatide
Arm Type
Experimental
Arm Description
Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo (matched to lixisenatide) QD for 24 Weeks.
Intervention Type
Drug
Intervention Name(s)
Lixisenatide (AVE0010)
Other Intervention Name(s)
Lyxumia
Intervention Description
Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning Route of administration: Subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning Route of administration: Subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
Antidiabetic background therapy
Intervention Description
Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
Primary Outcome Measure Information:
Title
Absolute Change in HbA1c From Baseline to Week 24
Description
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last on-treatment observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed=participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.
Time Frame
Baseline, Week 24
Secondary Outcome Measure Information:
Title
Change in 2-Hour PPG From Baseline to Week 24
Description
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Time Frame
Baseline, Week 24
Title
Change in Average 7-point SMPG Profiles From Baseline to Week 24
Description
Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime three times in a week before baseline, before visit Week 12 and before visit week 26 and the average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug.
Time Frame
Baseline, Week 24
Title
Change in Body Weight From Baseline to Week 24
Description
Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug.
Time Frame
Baseline, Week 24
Title
Change in FPG From Baseline to Week 24
Description
Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug.
Time Frame
Baseline, Week 24
Title
Percentage of Participants Requiring Rescue Therapy During 24 Week Treatment Period
Description
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG >270 mg/dL (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >9%.
Time Frame
Baseline up to Week 24
Title
Change in Plasma Glucose Excursions From Baseline to Week 24
Description
Plasma glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the liquid standardized breakfast meal test, before study drug administration. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Time Frame
Baseline, Week 24
Title
Change in Total Daily Basal Insulin Dose From Baseline to Week 24 (in Participants Who Took Basal Insulin as Background Therapy)
Description
Change in basal insulin dose was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Time Frame
Baseline, Week 24
Title
Percentage of Participants With Symptomatic and Severe Symptomatic Hypoglycemia
Description
Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the participant required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.
Time Frame
First dose of study drug up to 3 days after the last dose administration (maximum of 171 days)
Title
Percentage of Participants With HbA1c Reduction >0.5% at Week 24 and Did Not Experienced Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia
Description
The on-treatment period for HbA1c assessment was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. The on-treatment period for symptomatic hypoglycemia assessment was defined as the time from the first dose of study drug up to 1 day after the last dose of study drug.
Time Frame
Week 24
Title
Percentage of Participants With Gastrointestinal Disorders
Time Frame
Up to Day 171

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria : Older participants, aged 70 years and above, with T2DM inadequately controlled on their current anti-diabetic pharmaceutical treatment regimen. Signed written informed consent. Exclusion criteria: At screening HbA1c ≤7.0% or >10% (Acknowledging that the threshold of 7% may not be appropriate for all older participants and that this was the responsibility of the investigator to include the participant based on an individual evaluation of the expected benefits of better glycemic control versus risk of hypoglycemia). At screening participants on both basal insulin and sulfonylurea or basal insulin and meglitinides. At screening FPG >250 mg/dL (>13.9 mmol/L). Type 1 diabetes mellitus or history of ketoacidosis within one year prior to the screening visit. Type 2 diabetes mellitus diagnosed less than 1 year prior to screening. Anti-diabetic treatment not at a stable regimen or initiated within the last 3 months prior to screening. Treatment within the 3 months preceding the screening with other anti-diabetic agent than allowed background therapy. Allowed therapy includes metformin, sulfonylurea (except glibenclamide >10mg, gliclazide >160mg), meglitinides (except repaglinide >6mg), pioglitazone and basal insulin and should follow local product circulars and labeling restrictions for the study population. Participants who had been on an approved or an investigational Glucagon-like peptide 1 (GLP-1) medication (exenatide, liraglutide, lixisenatide or others). History of severe hypoglycemia associated with symptoms unawareness or results in unconsciousness/coma/seizure in the 6 months prior to screening. BMI <22 or >40 kg/m^2. Malnutrition assessed clinically by the investigator or any sub-investigator and by Mini-Nutritional Assessment-Short Form (MNA-SF) score <12 in countries (the judgment of the investigator prevails on questionnaires scores). Cognitive disorder and dementia assessed clinically by the investigator or any sub investigator and by Mini Mental State Examination (MMSE) score <24 (the judgment of the investigator prevails on questionnaires scores), or any neurologic disorder that affected the participant's ability to participate in the study. Participant who had a glomerular filtration rate (eGFR) (using the Modification of Diet in Renal Disease (MDRD) formula <30ml/min/1.73m^2). Participant with severe or uncontrolled disease, or any clinically significant abnormality identified on physical examination or investigational clinical procedure that, in the judgment of the investigator or any sub-investigator, would preclude safe completion of the study or constrains efficacy assessment. Laboratory findings at the time of screening: Amylase and/or lipase: >3 times the upper limit of the normal (ULN) laboratory range Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times ULN Calcitonin >20 pg/mL (5.9 pmol/L). Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (i.e. worsening) and not controlled (i.e. prolonged nausea and vomiting) gastroesophageal reflux disease within 6 months prior to screening. History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease. Personal or immediate family history of medullary thyroid cancer or genetic conditions that predisposed to medullary thyroid cancer (e.g., multiple endocrine neoplasia syndromes). The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 840010
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Investigational Site Number 840015
City
Norwalk
State/Province
California
ZIP/Postal Code
90650
Country
United States
Facility Name
Investigational Site Number 840003
City
Miami
State/Province
Florida
ZIP/Postal Code
33156
Country
United States
Facility Name
Investigational Site Number 840012
City
Miami
State/Province
Florida
ZIP/Postal Code
33156
Country
United States
Facility Name
Investigational Site Number 840002
City
Des Moines
State/Province
Iowa
ZIP/Postal Code
50314
Country
United States
Facility Name
Investigational Site Number 840008
City
Oxon Hill
State/Province
Maryland
ZIP/Postal Code
20745
Country
United States
Facility Name
Investigational Site Number 840004
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20852
Country
United States
Facility Name
Investigational Site Number 840017
City
Biloxi
State/Province
Mississippi
ZIP/Postal Code
39531
Country
United States
Facility Name
Investigational Site Number 840009
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68131
Country
United States
Facility Name
Investigational Site Number 840016
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Facility Name
Investigational Site Number 840006
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58103
Country
United States
Facility Name
Investigational Site Number 840014
City
Canal Fulton
State/Province
Ohio
ZIP/Postal Code
44614
Country
United States
Facility Name
Investigational Site Number 840011
City
St. George
State/Province
Utah
ZIP/Postal Code
84790
Country
United States
Facility Name
Investigational Site Number 840007
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53209
Country
United States
Facility Name
Investigational Site Number 036002
City
Box Hill
ZIP/Postal Code
3128
Country
Australia
Facility Name
Investigational Site Number 036006
City
Brookvale
ZIP/Postal Code
2100
Country
Australia
Facility Name
Investigational Site Number 036004
City
Camperdown
ZIP/Postal Code
2050
Country
Australia
Facility Name
Investigational Site Number 036005
City
Gosford
ZIP/Postal Code
2250
Country
Australia
Facility Name
Investigational Site Number 036001
City
Heidelberg
ZIP/Postal Code
3081
Country
Australia
Facility Name
Investigational Site Number 036003
City
Parkville
ZIP/Postal Code
3050
Country
Australia
Facility Name
Investigational Site Number 100002
City
Plovdiv
ZIP/Postal Code
4002
Country
Bulgaria
Facility Name
Investigational Site Number 100005
City
Plovdiv
ZIP/Postal Code
4002
Country
Bulgaria
Facility Name
Investigational Site Number 100003
City
Sofia
ZIP/Postal Code
1632
Country
Bulgaria
Facility Name
Investigational Site Number 100004
City
Stara Zagora
ZIP/Postal Code
6000
Country
Bulgaria
Facility Name
Investigational Site Number 100001
City
Varna
ZIP/Postal Code
9000
Country
Bulgaria
Facility Name
Investigational Site Number 124003
City
Hamilton
ZIP/Postal Code
L8L 5G8
Country
Canada
Facility Name
Investigational Site Number 124007
City
London
ZIP/Postal Code
N6B 2E3
Country
Canada
Facility Name
Investigational Site Number 124002
City
Sherbrooke
ZIP/Postal Code
J1H 5N4
Country
Canada
Facility Name
Investigational Site Number 124001
City
St-Romuald
ZIP/Postal Code
G6W 5M6
Country
Canada
Facility Name
Investigational Site Number 124005
City
Vancouver
ZIP/Postal Code
V5Z 1M9
Country
Canada
Facility Name
Investigational Site Number 124006
City
Vancouver
ZIP/Postal Code
V5Z 1M9
Country
Canada
Facility Name
Investigational Site Number 124008
City
Westmount
ZIP/Postal Code
H3Z 1E5
Country
Canada
Facility Name
Investigational Site Number 124004
City
Winnipeg
ZIP/Postal Code
R3E 3P4
Country
Canada
Facility Name
Investigational Site Number 208005
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Facility Name
Investigational Site Number 208001
City
København Nv
ZIP/Postal Code
2400
Country
Denmark
Facility Name
Investigational Site Number 208004
City
København S
ZIP/Postal Code
2300
Country
Denmark
Facility Name
Investigational Site Number 208002
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Facility Name
Investigational Site Number 208003
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark
Facility Name
Investigational Site Number 276005
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Investigational Site Number 276004
City
Essen
ZIP/Postal Code
45359
Country
Germany
Facility Name
Investigational Site Number 276002
City
München
ZIP/Postal Code
80639
Country
Germany
Facility Name
Investigational Site Number 276001
City
Münster
ZIP/Postal Code
48145
Country
Germany
Facility Name
Investigational Site Number 276006
City
Pirna
ZIP/Postal Code
01796
Country
Germany
Facility Name
Investigational Site Number 276007
City
Pohlheim
ZIP/Postal Code
35415
Country
Germany
Facility Name
Investigational Site Number 276008
City
Potsdam
ZIP/Postal Code
14469
Country
Germany
Facility Name
Investigational Site Number 276003
City
Saarlouis
ZIP/Postal Code
66740
Country
Germany
Facility Name
Investigational Site Number 578001
City
Hønefoss
ZIP/Postal Code
3515
Country
Norway
Facility Name
Investigational Site Number 578005
City
Kongsvinger
ZIP/Postal Code
2212
Country
Norway
Facility Name
Investigational Site Number 578003
City
Oslo
Country
Norway
Facility Name
Investigational Site Number 578006
City
Stavanger
ZIP/Postal Code
4095
Country
Norway
Facility Name
Investigational Site Number 578004
City
Trondheim
ZIP/Postal Code
7012
Country
Norway
Facility Name
Investigational Site Number 604001
City
Arequipa
Country
Peru
Facility Name
Investigational Site Number 604011
City
Lima
ZIP/Postal Code
27
Country
Peru
Facility Name
Investigational Site Number 604005
City
Lima
ZIP/Postal Code
LIMA 10
Country
Peru
Facility Name
Investigational Site Number 604003
City
Lima
ZIP/Postal Code
LIMA 14
Country
Peru
Facility Name
Investigational Site Number 604006
City
Lima
ZIP/Postal Code
LIMA 31
Country
Peru
Facility Name
Investigational Site Number 604002
City
Lima
Country
Peru
Facility Name
Investigational Site Number 604007
City
Lima
Country
Peru
Facility Name
Investigational Site Number 604008
City
Piura
Country
Peru
Facility Name
Investigational Site Number 616004
City
Gdansk
ZIP/Postal Code
80-858
Country
Poland
Facility Name
Investigational Site Number 616003
City
Krakow
ZIP/Postal Code
31-024
Country
Poland
Facility Name
Investigational Site Number 616001
City
Poznan
ZIP/Postal Code
61-665
Country
Poland
Facility Name
Investigational Site Number 616002
City
Ruda Slaska
ZIP/Postal Code
41-709
Country
Poland
Facility Name
Investigational Site Number 616006
City
Szczecin
ZIP/Postal Code
70-506
Country
Poland
Facility Name
Investigational Site Number 710003
City
Cape Town
ZIP/Postal Code
7500
Country
South Africa
Facility Name
Investigational Site Number 710002
City
Cape Town
ZIP/Postal Code
7530
Country
South Africa
Facility Name
Investigational Site Number 710004
City
Somerset West
ZIP/Postal Code
7130
Country
South Africa
Facility Name
Investigational Site Number 724001
City
Alcira
ZIP/Postal Code
46600
Country
Spain
Facility Name
Investigational Site Number 724005
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Investigational Site Number 724006
City
Hostalets De Balenyà
ZIP/Postal Code
08550
Country
Spain
Facility Name
Investigational Site Number 724003
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Investigational Site Number 724002
City
Sanlúcar De Barrameda
ZIP/Postal Code
11540
Country
Spain
Facility Name
Investigational Site Number 724004
City
Santiago De Compostela
ZIP/Postal Code
15706
Country
Spain
Facility Name
Investigational Site Number 752006
City
Göteborg
ZIP/Postal Code
405 45
Country
Sweden
Facility Name
Investigational Site Number 752007
City
Härnösand
ZIP/Postal Code
871 82
Country
Sweden
Facility Name
Investigational Site Number 752002
City
Lund
ZIP/Postal Code
22221
Country
Sweden
Facility Name
Investigational Site Number 752004
City
Malmö
ZIP/Postal Code
211 52
Country
Sweden
Facility Name
Investigational Site Number 752003
City
Stockholm
ZIP/Postal Code
111 57
Country
Sweden
Facility Name
Investigational Site Number 752001
City
Stockholm
ZIP/Postal Code
171 76
Country
Sweden
Facility Name
Investigational Site Number 826003
City
Bexhill-On-Sea
ZIP/Postal Code
TN39 4SP
Country
United Kingdom
Facility Name
Investigational Site Number 826001
City
Glasgow
Country
United Kingdom
Facility Name
Investigational Site Number 826002
City
Irvine
ZIP/Postal Code
KA12 0AY
Country
United Kingdom
Facility Name
Investigational Site Number 826004
City
Trowbridge
ZIP/Postal Code
BA14 8QA
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
28188240
Citation
Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, Manrique Hurtado H, Guo H, Pilorget V, Perfetti R, Simpson H; GetGoal-O Trial Investigators. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. Diabetes Care. 2017 Apr;40(4):485-493. doi: 10.2337/dc16-2143. Epub 2017 Feb 10.
Results Reference
result

Learn more about this trial

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

We'll reach out to this number within 24 hrs